Price Vision Group Blog

THE LATEST NEWS FROM PRICE VISION GROUP

19/Aug/2020

Trefoil Therapeutics Begins First Clinical Trial at Price Vision Group for Patients with Corneal Endothelial Dystrophies

SAN DIEGO–(BUSINESS WIRE)–Trefoil Therapeutics today announced it has initiated the first clinical trial of its engineered Fibroblast Growth Factor-1 TTHX1114 for the treatment of people with corneal endothelial dystrophies (CED), including Fuchs Endothelial Corneal Dystrophy. To read the full press release, please click here.

 


Price Vision Group logo horiz white

Price Vision Group is a global leader in corneal transplant, cataract surgery, keratoconus treatment, PRK and LASIK. At our center in Indianapolis, we see patients from Indiana cities including Zionsville, Fishers, Carmel, Noblesville, Avon, and Greenwood, as well as people who travel from across the U.S. and even abroad for treatment by our renowned physicians.

Copyright 2024 Price Vision Group. All rights reserved.

(317) 844-5530